S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
NYSE:EBS

Emergent BioSolutions (EBS) Stock Price, News & Analysis

$2.55
-0.04 (-1.54%)
(As of 03:51 PM ET)
Today's Range
$2.45
$2.72
50-Day Range
$1.49
$3.41
52-Week Range
$1.42
$13.67
Volume
897,414 shs
Average Volume
3.13 million shs
Market Capitalization
$133.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Emergent BioSolutions MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
93.8% Upside
$5.00 Price Target
Short Interest
Healthy
9.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
0.40mentions of Emergent BioSolutions in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($13.98) to ($0.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.44 out of 5 stars

Medical Sector

99th out of 939 stocks

Pharmaceutical Preparations Industry

39th out of 433 stocks

EBS stock logo

About Emergent BioSolutions Stock (NYSE:EBS)

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

EBS Stock Price History

EBS Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Emergent BioSolutions Shares Drop on S&P Downgrade
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Q4 2023 Emergent BioSolutions Inc Earnings Call
Emergent BioSolutions: Q4 Earnings Insights
Emergent BioSolutions's Earnings: A Preview
Biotech with Baltimore facility taps new CEO
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
Emergent names Joseph Papa as new CEO
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
CUSIP
29089Q10
Employees
1,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+89.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-760,500,000.00
Pretax Margin
-69.68%

Debt

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$0.95 per share
Book Value
$12.51 per share

Miscellaneous

Free Float
51,211,000
Market Cap
$137.81 million
Optionable
Optionable
Beta
1.22
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Richard S. Lindahl M.B.A.Mr. Richard S. Lindahl M.B.A. (Age 60)
    Executive VP, CFO & Treasurer
    Comp: $799.38k
  • Ms. Jennifer L. Fox
    Executive VP of External Affairs, General Counsel & Corporate Secretary
  • Mr. Joseph C. Papa Jr. (Age 68)
    CEO & President
  • Mr. Robert G. Burrows
    Vice President of Investor Relations
  • Ms. Coleen Glessner
    Executive Vice President of Global Quality and Ethics & Compliance
  • Michelle Pepin
    Senior VP & Chief Human Resource Officer
  • Ms. Stephanie Duatschek
    Senior VP, Chief Strategy & Transformation Officer
  • Dr. Kelly Lyn Warfield
    Senior VP of Science & Development
  • Mr. Paul A. Williams
    Senior Vice President of Products Business
  • William Hartzel
    Senior Vice President of Manufacturing & Bioservices

EBS Stock Analysis - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price target for 2024?

2 Wall Street analysts have issued twelve-month target prices for Emergent BioSolutions' stock. Their EBS share price targets range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 93.8% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2024?

Emergent BioSolutions' stock was trading at $2.40 at the start of the year. Since then, EBS shares have increased by 7.5% and is now trading at $2.58.
View the best growth stocks for 2024 here
.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 4,910,000 shares, a drop of 20.8% from the February 29th total of 6,200,000 shares. Based on an average daily volume of 3,000,000 shares, the short-interest ratio is presently 1.6 days. Currently, 9.8% of the shares of the stock are short sold.
View Emergent BioSolutions' Short Interest
.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings data on Wednesday, March, 6th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.44. The biopharmaceutical company earned $276.60 million during the quarter, compared to analyst estimates of $247.63 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 37.35% and a negative net margin of 72.11%. During the same period in the prior year, the firm posted ($0.31) EPS.

What ETF holds Emergent BioSolutions' stock?

Amplify Treatments, Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$250.0 million, compared to the consensus revenue estimate of $185.4 million.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.73%), Vanguard Group Inc. (5.73%), Charles Schwab Investment Management Inc. (5.54%), Hotchkis & Wiley Capital Management LLC (3.18%), Assenagon Asset Management S.A. (1.61%) and Goldman Sachs Group Inc. (1.45%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl and Ronald Richard.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:EBS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners